Share

Media advisory: Mayo Clinic study finds infliximab ‘safe and beneficial’ for Crohn’s disease

Video Feed: A video feed, including sound bites from the study’s principal investigator, a patient interview and b-roll will be fed via satellite at 3 p.m. CST on Tues., March 13, 2001.

Media Advisory

WHAT: Mayo Clinic Study Finds Infliximab ‘Safe and Beneficial’ for Crohn’s disease

A new drug for treating Crohn’s disease (CD), infliximab, (Remicade, Centocor Inc.), is safe and beneficial for patients who have not gotten relief from other medications, according to findings of a Mayo Clinic study published in the March issue of the American Journal of Gastroenterology. Of the first 100 Mayo Clinic patients to receive infliximab infusions, 72 experienced a positive response.

WHEN: Tuesday, March 13, 2001

Eastern Central Test: 16:00-16:05 (EST) 15:00-15:05 (CST) Program: 16:05-16:30 15:05-15:30

Satellite Coordinates Ku-Band / C-Band Satellite: Galaxy 11 / Galaxy 4 Transponder: 16 (V) / 12 (V) Channel: 16 / 12 Downlink Frequency: 12020 MHz / 3940 MHz Audio: 6.2 or 6.8 MHz / 6.2 or 6.8 MHz Longitude: 91° W / 99° W

Technical Questions Prior to Broadcast ONLY: 507-284-5964 (Mayo Clinic Video Communications) Satellite Technical Difficulties: 800-608-3663 (Strategic Television)

Share

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.